← SynDRA
CANERTINIB
SynDRA canonical compound SYN0001722 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | ERBB4 |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- ERBB2 INHIBITOR
- Receptor protein-tyrosine kinase erbB-2 inhibitor
- ERBB4 INHIBITOR
- Receptor protein-tyrosine kinase erbB-4 inhibitor
- AKT1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- EPHA6
- MAP2K2
- MAP2K7
- CSNK1D
- CSNK1E
- CSNK1G2
- MAP2K5
- CTSC
- RPS6KA1
- STK17A
- MAP2K1
- LYN
- LTK
- RIPK3
- RIPK2
- LRRK2
- CSK
- COQ8B
- COQ8A
- PDGFRB
- SIK2
- SIK3
- PDGFRA
- MAP3K19
- SLK
- MAP3K2
- MAP3K20
- MAP3K3
- MAP3K4
- SRC
- SRMS
- MAP3K7
- STK10
- DDR1
- RIOK1
- RET
- EPHB1
- HCK
- GAK
- FYN
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- ATXN2
- TP53
- TGFR2
- SMAD3
- SMAD2
- RARA
- PRGR
- NTMT1
- NTM1A
- NSD2
- NR1I2
- NR1H4
- NF2L2
- MP2K1
- MK06
- M4K5
- M3K20
- KSYK
- IFNB1
- HSPB1
- HLAB
- GLI3
- GCR
- ESRRA
- ESR1
- CTRO
- CREB1
- CP3A4
- CASP7
- CASP3
- TSHR
Drug classes
- Anesthetics, Local
- Antineoplastic Agents
- Cardiotonic Agents
Cross-references
Synonyms
- CANERTINIB (CI-1033)
- Canertinib dihydrochloride
- CI-1033
- GW781483X
- PD-0183805
- PD-183805
- PD183805
- SN-26606
- Canertinib HCl
- Canertinib dihydrochloride [USAN]
- CI1033
- Canertinib dihydrochloride (USAN)
- Canertinib, PD-183805, CI1033, PD183805
- N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride
- N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
- N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride
- N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride
- N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
- N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide
- 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride
- 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride
- Canertinib free base
- N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide
- C78W1K5ASF
- CHEMBL31965
- CHEBI:61399
- 267243-28-7 (free base)
- NCGC00182713-01
- Canertinib (CI-1033)
- Canertinib [INN]
- Canertinib [INN:BAN]
- CI-1033(Canertinib)
- UNII-C78W1K5ASF
- CANETINIB
- CANERTINIB [MI]
- Caneritinib; CI-1033
- Canertinib - CI-1033
Look up CANERTINIB in the interactive SynDRA portal →